Massive PNH registry tracks drug safety and disease course
NCT ID NCT01374360
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study collected data from over 6,000 people with PNH to monitor the safety of two drugs, Soliris and Ultomiris, and understand how the disease progresses. Participants included patients of any age who had a PNH diagnosis or a PNH clone. The goal was to track serious events like infections, blood clots, and organ problems, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations.
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.